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A B S T R A C T
Prolonged exposure to hyperoxia produces extraordinary amounts of reactive oxygen species (ROS) in the lung
and causes hyperoxic lung injury. Although supraphysiological oxygen is routinely administered for the
management of respiratory failure, there is no eﬀective strategy to prevent hyperoxic lung injury. In our previous
study, we showed that suplatast tosilate, an asthma drug that inhibits T helper 2 (Th2) cytokines, ameliorated
bleomycin-induced lung injury and ﬁbrosis through Th2-independent mechanisms. Because bleomycin also
generates ROS, we hypothesized that suplatast tosilate might have antioxidant activity and protect the lung
against hyperoxic lung injury. To test this hypothesis, mice exposed to hyperoxia were given suplatast tosilate
through drinking water. Treatment with suplatast tosilate signiﬁcantly prolonged mouse survival, reduced the
increases in the numbers of inﬂammatory cells, levels of the pro-inﬂammatory cytokines/chemokines IL-6 and
MCP-1, and protein in bronchoalveolar lavage ﬂuid, and ameliorated lung injury in histological assessment.
Suplatast tosilate treatment also signiﬁcantly inhibited hyperoxia-induced elevations in the levels of 8-
hydroxydeoxyguanosine, a marker of oxidative DNA damage, in bronchoalveolar lavage ﬂuid and 8-isoprostane,
a marker of lipid peroxidation, in lung tissue. This ﬁnding suggests that suplatast tosilate exerts an antioxidant
activity in vivo. In addition, we investigated whether suplatast tosilate has a scavenging eﬀect on hydroxyl
radical, the most reactive and harmful ROS, using electron paramagnetic resonance spin-trapping. Suplatast
tosilate was shown to scavenge hydroxyl radicals in a dose-dependent manner, and its reaction rate constant
with hydroxyl radical was calculated as 2.6×1011 M−1 S−1, which is faster than that of several well-established
antioxidants, such as ascorbate, glutathione, and cysteine. These results suggest that suplatast tosilate protects
the lung against hyperoxic lung injury by decreasing the degree of oxidative stress induced by ROS, particularly
by scavenging hydroxyl radicals. Suplatast tosilate might become a potential therapeutic for hyperoxic lung
injury.
1. Introduction
High concentrations of oxygen are routinely applied for the manage-
ment of patients with severe respiratory failure, such as acute lung injury
and acute respiratory distress syndrome (ARDS). However, prolonged
exposure to high concentrations of oxygen can cause hyperoxic lung
injury that mimics the disease condition of ARDS [1–6]. Reactive oxygen
species (ROS), such as superoxide anion, hydrogen peroxide, and
hydroxyl radical, generated under hyperoxic conditions are strongly
involved in this lung injury. ROS cause cellular damage by delivering
oxidative insults to DNA, proteins, and membranes and by inducing an
inﬂammatory response in the injured lung tissue. Inﬂammatory cells that
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accumulate in the lung also generate ROS, and the lung injury progres-
sively worsens [7–9]. In the management of patients with acute lung
injury or ARDS, administration of supraphysiological concentrations of
oxygen is required to maintain adequate tissue oxygenation; unfortu-
nately, however, there are no pharmacological therapies to attenuate the
resulting hyperoxic lung injury.
Some drugs frequently cause lung injury by generating ROS in the
lung; the representative example is bleomycin [10,11]. Because bleo-
mycin is a strong redox-active agent capable of inducing oxidative
cleavage of DNA, it is used as an antitumor agent [12]. In mice,
intratracheal administration of bleomycin elicits severe inﬂammation in
the lung, followed by pulmonary ﬁbrosis. Interestingly, a previous
study from our laboratory reported that suplatast tosilate, an anti-
allergic agent only available in Japan, strongly inhibited bleomycin-
induced lung injury and ﬁbrosis [13]. Suplatast tosilate (Fig. 1) is
widely used as an oral asthma control drug in Japan because it inhibits
the production of T helper 2 (Th2) cytokines in animal models of
bronchial asthma [14–16]. Although suplatast tosilate has also been
prescribed for adult and pediatric patients with allergic rhinitis and
atopic dermatitis for more than 20 years in Japan, its long-term toxicity
has not been reported.
The risk of serious side eﬀects from suplatast tosilate is extremely
low; however, its precise mechanism of action is not fully understood.
Nonetheless, we have shown that the inhibitory eﬀect of suplatast
tosilate on bleomycin-induced lung injury and ﬁbrosis was not
mediated by its action on Th2 cytokines [13]. To the best of our
knowledge, there are no new data explaining the anti-allergic action of
suplatast tosilate.
Based on these observations, we speculated that suplatast tosilate
inhibited bleomycin-induced lung injury and ﬁbrosis via an antioxidant
activity that removed the ROS generated by bleomycin. In other words,
we hypothesized that suplatast tosilate might have a ROS scavenging
activity. To test this hypothesis, we investigated the eﬀects of suplatast
tosilate on mice with hyperoxic lung injury, the most prominent animal
model for lung injury induced by oxidative stress. In addition, the
scavenging eﬀect of suplatast tosilate on hydroxyl radical, a represen-
tative ROS, was also analyzed by using electron paramagnetic reso-
nance (EPR; also known as electron spin resonance [ESR]) spin-
trapping.
2. Materials and methods
2.1. Animals
Speciﬁc pathogen-free, female C57BL/6 mice weighing 20–22 g
were purchased from Charles River Laboratories Japan (Yokohama,
Japan). The animals were housed in pathogen-free rooms and main-
tained on laboratory chow, with free access to food and water. The
committee on animal research at the University of Hiroshima approved
all procedures.
2.2. Oxygen exposure
The mice were exposed to hyperoxia (90± 92%) in a sealed 30-l
chamber (Allentown, Inc., Allentown, NJ, USA). Food and water were
provided ad libitum. Oxygen, provided by an oxygen concentrator (TO-
90-5H; Teijin, Tokyo, Japan), was delivered to the chamber to provide
eight changes per hour (5 l/min ﬂow rate).
2.3. Administration of suplatast tosilate
Suplatast tosilate was synthesized and supplied by Taiho
Pharmaceutical Co. Ltd. (Tokyo, Japan). Suplatast tosilate, dissolved
in drinking water at 1 mg/ml, was given to mice ad libitum because we
found that oral gavage administration could weaken and even kill mice.
From the amount of water drunk, the dose of suplatast tosilate was
approximately calculated as 100 mg/kg/day. To prove that suplatast
tosilate has a protective eﬀect in hyperoxic lung injury, its administra-
tion was started 2 days before the start of hyperoxic exposure. Detailed
data regarding the pharmacokinetics of suplatast tosilate after oral
administration in rodents were reported in previous studies [29–31].
2.4. Bronchoalveolar lavage and cell analysis
The trachea was exposed via a midline incision and cannulated with
a tracheal cannula, and the lungs were lavaged three times with 0.5 ml
of phosphate-buﬀered saline. The lavage ﬂuids were pooled and
centrifuged at 300g for 10 min at 4 °C. The supernatants were stored
at−80 °C before measurement of cytokine and protein concentrations.
The cell pellets were resuspended in 1 ml of Dulbecco's modiﬁed Eagle's
medium, and the total cell numbers were counted using a hemocyt-
ometer. Diﬀerential cell counts were performed by counting at least 300
cells on a smear prepared using a cytospin (Shandon Inc., Pittsburgh,
PA, USA) that was stained with the Diﬀ-Quik stain set (Kokusai
Shiyaku, Kobe, Japan).
2.5. Histological examination
The lung tissue specimens of the mice were ﬁxed by inﬂation with a
buﬀered 10% formalin solution. Lung tissue specimens were embedded
in paraﬃn, and the sections were stained with hematoxylin and eosin
and thereafter examined by light microscopy.
2.6. Protein concentration
The protein concentrations in samples were determined using a BCA
protein assay kit (Pierce, Rockford, IL, USA) following the manufac-
turer's instructions.
2.7. Cytokine measurements
Commercially available ELISA kits for IL-6 and MCP-1 were
obtained from R&D Systems (Minneapolis, MN, USA). The concentra-
tion of each cytokine in the sample was measured following the
manufacturer's protocols.
2.8. Total and diﬀerential white blood cell counts
About 0.5 ml of blood was drawn from the inferior vena cava and
transferred into EDTA tubes. Total and diﬀerential white blood cell
counts were performed using a TC20™ automated cell counter (Bio-Rad,
Hercules, CA, USA).
2.9. Quantiﬁcation of 8-isoprostane
Lung tissue was obtained after 24, 48, and 90 h of hyperoxia. To
prevent auto-oxidation, lung tissue was immediately ﬂash frozen in
liquid nitrogen at harvest and stored at –80 °C until analysis. Upon
thawing, the tissue sample was homogenized in 3 ml of phosphate-
buﬀed saline and centrifuged. The 8-isoprostane content of the super-
natants was analyzed using an Oxiselect 8-iso-prostaglandin F2α ELISA
Kit (Cell Biolabs, Inc., San Diego, CA, USA) according to the manufac-
turer's instructions.
Fig. 1. Chemical structure of suplatast tosilate.
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2.10. Quantiﬁcation of 8-hydroxydeoxyguanosine
As an indicator of oxidative DNA damage, 8-hydroxydeoxyguano-
sine (8-OHdG) was measured in the bronchoalveolar lavage (BAL) ﬂuid
obtained after 24, 48, and 90 h of hyperoxia using the Highly Sensitive
ELISA kit for 8-OHdG (NIKKEN SEIL Co., Ltd., Shizuoka, Japan).
2.11. Quantiﬁcation of myeloperoxidase
Myeloperoxidase (MPO) activity was measured in the lung tissue
homogenates obtained after 24, 48, and 90 h of hyperoxia using the
MPO Mouse ELISA Kit (Abcam, Cambridge, UK), following the manu-
facturer's instructions.
2.12. Assessment of Nrf-2 expression in the lung
Total RNA was isolated from the lungs of mice after 72 h of
hyperoxic exposure using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). Isolated total RNA was reverse transcribed into cDNA, and
real-time quantitative RT-PCR was performed with sequence-speciﬁc
TaqMan primers and probes for Nrf-2 and the housekeeping gene 18 S
rRNA using the ABI Prism 7500 Fast Sequence Detector and SDS
analysis software (Applied Biosystems, Foster City, CA, USA). The
mRNA level of Nrf-2 was expressed relative to the level of its internal
reference, 18S rRNA.
2.13. EPR spin-trapping analysis of hydroxyl radicals
5,5-Dimethylpyrroline-N-oxide (DMPO) was purchased from
LABOTEC Co., Ltd. (Tokyo, Japan), and hydrogen peroxide and ferrous
iron (FeSO4) were obtained from Wako Pure Chemicals (Osaka, Japan).
The capacity of suplatast tosilate to scavenge hydroxyl radicals was
examined by EPR spin-trapping using DMPO as a reference trapping
agent because it reacts with hydroxyl radicals to form a spin adduct.
Hydroxyl radicals were generated by the Fenton reaction started by the
addition of hydrogen peroxide (12.4 mM ﬁnal concentration) to a
reaction mixture containing FeSO4 (0.2 mM ﬁnal concentration) and
DMPO (20 μM ﬁnal concentration) in the presence of varying concen-
trations of suplatast tosilate in 66.7 mM phosphate buﬀer solution (pH
7.4). The EPR signal was measured 1 min after the start of the reaction.
EPR spectra were recorded using an ELEXSYS E500 CW-EPR
spectrometer (Bruker BioSpin K.K., Kanagawa, Japan). The measure-
ments were carried out under the following conditions: magnetic ﬁeld,
347–357 mT; microwave power, 12.0 mW; frequency, 100 kHz; mod-
ulation amplitude, 0.1 mT (1.0 Gauss); sweep time, 168 s; time
constant, 163.8 ms; received gain, ×66; and temperature, 24 °C.
These EPR analyses were performed by the Organic Analysis and
Environmental Analysis Team in the Analysis Center of the Panasonic
Corporation, Osaka, Japan. The reaction rate of suplatast tosilate with
hydroxyl radicals was calculated by using a competition reaction
between DMPO and suplatast tosilate with hydroxyl radicals, as
previously described [17–19]. The calculation process is shown brieﬂy
as follows. Hydroxyl radicals (･OH) react with DMPO or suplatast
tosilate (ST) in the reaction system. The reactions produce the two
intermediate products (Eqs. (1) and (2)), where kDMPO and kST represent
the reaction rate constants of DMPO with hydroxyl radicals and
suplatast tosilate with hydroxyl radicals, respectively. The rate constant
of kDMPO has been reported to be 4.3×109 M−1 S−1 [19,20].
OH DMPO DMPO OH∙ + ⟹ −
kDMPO (1)
OH ST ST OH∙ + ⟹ −
kST (2)
The EPR signal intensity of DMPO-OH (DMPO spin adduct of
hydroxyl radicals) was recorded in the absence and presence of
suplatast tosilate.
d DMPO OH dt k DMPO OH[ − ]/ = [ ][∙ ]DMPO (3)
d ST OH dt k ST OH[ − ]/ = [ ][∙ ]ST (4)
In the competitive reaction, the reduction amounts of DMPO-OH
should be equal to the amounts scavenged by suplatast tosilate. Hence,
Eq. (5) can be deduced from Eqs. (3) and (4).
d DMPO OH dt d ST OH dt X X[ − ]/ : [ − ]/ = (1 − ): (5)
Here, the variable X (0<X<1) is the inhibition rate of the DMPO-
OH signal. From Eqs. (3), (4), and (5), Eq. (6) can be deduced.
k k X X DMPO ST= { /(1 − )}∙{[ ]/[ ]}ST DMPO (6)
When the concentration of DMPO-OH decreases by 50%, Eq. (6) can
be simpliﬁed by substituting 0.5 for X.
k k DMPO IC= [ ]/ST DMPO 50 (7)
The IC50 represents the concentration of suplatast tosilate that
quenches 50% of hydroxyl radicals. Furthermore, kST can be obtained
from the slope of the linear regression plot of X/1–X versus the
concentration of suplatast tosilate [ST].
2.14. Statistical analysis
Statistical analyses were performed using SPSS 17 (SPSS Japan,
Tokyo, Japan). Data are presented as the mean± SEM. Student's t-test
was used to evaluate statistical diﬀerences between the groups. The
Kaplan-Meier method was used for survival analysis and comparisons
were made using a log-rank test. Diﬀerences were considered signiﬁ-
cant when the p value was <0.05.
3. Results
3.1. Eﬀect of suplatast tosilate on survival from lethal hyperoxia in mice
To determine whether suplatast tosilate exerts a beneﬁcial eﬀect on
survival from lethal hyperoxia in mice, survival was compared between
mice administered suplatast tosilate in drinking water (suplatast
tosilate-treated group) and mice given only water (control group)
during hyperoxic exposure. As shown in Fig. 2A, treatment with
suplatast tosilate signiﬁcantly prolonged survival in mice exposed to
hyperoxia. In our mouse hyperoxia model, we found that, after 80 h of
hyperoxia, the control group mice became ill, manifested tachypnea,
and started dying, although there were no diﬀerences in the body
weights and food intake between the two groups of mice given water
and suplatast tosilate until then. We were thus interested in seeing the
eﬀect of suplatast tosilate on survival in mice exposed to hyperoxia for
80 h and then returned to room air. Interestingly, no death occurred in
the suplatast tosilate-treated group exposed to hyperoxia for 80 h and
returned to room air, whereas a rapid decrease in survival rate was
observed in the control group mice immediately after their return to
room air (Fig. 2B). Treatment with suplatast tosilate also conferred a
prominent survival advantage in the transient hyperoxic exposure
model.
3.2. Eﬀect of suplatast tosilate on hyperoxic lung injury
To determine whether suplatast tosilate aﬀects the degree of
hyperoxic lung injury, the microscopic features of the lungs and the
protein concentrations in BAL ﬂuid were compared between the mice of
the suplatast tosilate-treated and control groups. As shown in Fig. 3,
hyperoxic exposure induced interstitial inﬂammation and edema in the
mouse lungs of both groups that exacerbated over time, but the severity
of these conditions was much lower in the suplatast tosilate-treated
group.
The protein concentration in BAL ﬂuid, which reﬂects protein
leakage into the alveolar space, also increased over time after hyperoxic
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exposure in the mice of both the suplatast tosilate-treated and control
groups. However, the protein concentration was signiﬁcantly lower in
the suplatast tosilate-treated group mice than in the control group mice
after 72 and 90 h of hyperoxia (Fig. 4A).
3.3. Eﬀect of suplatast tosilate on inﬂammatory indices in BAL ﬂuid
To evaluate the inﬂammatory response in the lung during hyperoxic
exposure, the numbers of inﬂammatory cells were counted and the
levels of the inﬂammatory cytokines/chemokines IL-6 and MCP-1 were
measured in BAL ﬂuid obtained from the mice of the suplatast tosilate-
treated and control groups. The recovery rate of BAL ﬂuid typically
exceeded 85% and did not diﬀer between the experimental groups.
Because lymphocytes and eosinophils were scarcely observed in the
BAL ﬂuid obtained from the mice exposed to hyperoxia (data not
shown), the macrophage and neutrophil counts are presented. As the
hyperoxic lung injury progressed, the numbers of macrophages and
neutrophils in BAL ﬂuid increased in the mice of both groups. However,
they were signiﬁcantly lower in suplatast tosilate-treated group mice
than in control mice after 72 and 90 h of hyperoxia (Fig. 4B and C). As
shown in Fig. 5, the levels of IL-6 and MCP-1 in BAL ﬂuid abruptly
increased from 72 to 90 h of hyperoxic exposure in the mice of both
groups. Similar to the inﬂammatory cells, treatment with suplatast
tosilate signiﬁcantly decreased the levels of both IL-6 and MCP-1 in BAL
ﬂuid after 72 and 90 h of hyperoxia (Fig. 4D and E). We also measured
the Th2 cytokines IL-4 and IL-5 in BAL ﬂuids but their levels were below
the detection limits of the ELISA kits at all time points examined in both
groups.
3.4. Eﬀect of suplatast tosilate on total and diﬀerential white blood cell
counts during hyperoxic exposure
To evaluate the changes in white blood cell counts during hyperoxic
exposure, we counted the numbers of total white cells and neutrophils
in peripheral blood at baseline and after 24, 48, 72, and 90 h of
Fig. 3. Lung histology of mice given water or suplatast tosilate during hyperoxic exposure. Formalin-ﬁxed sections of mouse lungs were stained with hematoxylin and eosin. Mice were
given water at baseline (A), after 48 h of hyperoxic exposure (C), and after 90 h of hyperoxic exposure (E). Mice were given suplatast tosilate at baseline (B), after 48 h of hyperoxic
exposure (D), and after 90 h of hyperoxic exposure (F). Scale bars, 100 µm.
Fig. 2. Survival analysis of mice during and after hyperoxic exposure. (A) Survival was
assessed when mice given suplatast tosilate (squares) or water (open circle) were exposed
to 90% O2 continuously until all of the mice had died (n=7 mice/group). (B) Survival
was assessed when mice given suplatast tosilate (squares) or water (open circle) were
exposed to 90% O2 for 80 h and returned to the room air condition (n=5 mice/group).
Asterisks indicate signiﬁcant diﬀerences determined by Kaplan-Meier analysis. *p< 0.05,
**p< 0.01.
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hyperoxic exposure. As shown in Fig. 5, the numbers of neutrophils in
the peripheral blood of mice given water decreased after 48 h of
hyperoxic exposure compared with those at baseline and 24 h of
hyperoxic exposure and then drastically increased at 72 and 90 h of
hyperoxic exposure; in contrast, those of mice given suplatast tosilate
did not change during hyperoxic exposure. This decrease in peripheral
Fig. 4. Total protein concentration (A), numbers of macrophages (B) and neutrophils (C), and concentrations of IL-6 (D) and MCP-I (E) in bronchoalveolar lavage (BAL) ﬂuid from mice
given water or suplatast tosilate during hyperoxic exposure. BAL was performed for mice given water (open bars) or suplatast tosilate (solid bars) at baseline and after 24, 48, 72, and 90 h
of hyperoxic exposure. The data are shown as the means± SEM (n=7 mice/group). *p< 0.05 versus mice given water, **p<0.01 versus mice given water.
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blood neutrophils must be caused by pulmonary sequestration of
neutrophils occurring at the initiation of harsh inﬂammation in the
lung.
3.5. Eﬀect of suplatast tosilate on hyperoxia-induced oxidative stress in the
lung
To test the hypothesis that suplatast tosilate exerts an antioxidant
eﬀect on hyperoxia-induced oxidative stress in the lung, we measured
8-OHdG, a marker of oxidative DNA damage, in BAL ﬂuid and 8-
isoprostane, a marker of lipid peroxidation, in lung tissue after 24, 48,
and 90 h of hyperoxia. As shown in Fig. 6A and B, the levels of both 8-
OHdG in BAL ﬂuid and 8-isoprostane in lung tissue signiﬁcantly
increased with time, and suplatast tosilate treatment signiﬁcantly
reduced both of these levels at each time point. To evaluate the amount
of activated neutrophils inﬁltrated into the lung, we also measured
MPO levels in lung tissues after 24, 48, and 90 h of hyperoxic exposure.
As shown in Fig. 6C, the levels of MPO in lung tissues were not diﬀerent
between mice given water and those given suplatast tosilate after 24
and 48 h of hyperoxic exposure. Notably, suplatast tosilate showed an
antioxidant eﬀect after 24 and 48 h of hyperoxic exposure when the
inﬂammation levels, particularly neutrophil inﬁltration, in the lung
were not diﬀerent between mice given water and those given suplatast
tosilate. Although we were not able to extract DNA from BAL ﬂuids and
thus quantify its amount, we conﬁrmed that there were no signiﬁcant
diﬀerences among the amounts of DNA extracted from any of the lung
tissue samples (data not shown).
To determine whether the Nrf-2 pathway is involved in the
antioxidant eﬀect of suplatast tosilate on hyperoxic lung injury, the
expression levels of Nrf-2 in the lungs were compared between mice
given water and those given suplatast tosilate after 72 h of hyperoxic
exposure. As shown in Fig. 7, no diﬀerence was found between them,
suggesting that the protective eﬀect of suplatast tosilate on hyperoxic
lung injury is not strongly mediated by the Nrf-2 pathway.
3.6. Hydroxyl radical-scavenging activity of suplatast tosilate evaluated by
EPR spin-trapping analysis
To test the hypothesis that suplatast tosilate exerts a scavenging
activity on ROS, the capacity of suplatast tosilate to scavenge hydroxyl
radical, a representative ROS, was examined using the EPR spin-
trapping method with DMPO as a reference trapping agent. Fig. 8A(a)
shows the EPR spectrum of the DMPO-hydroxyl radical spin adduct
without suplatast tosilate in the reaction mixture. When suplatast
tosilate was added to the reaction, the EPR signal intensity decreased
in proportion to the increase in the suplatast tosilate concentration
[Fig. 8A(b)–(d)]. From the slope of the linear plot (Fig. 8B and C), the
half-maximal inhibitory concentration was calculated as 3.4 μmol/ml
and the reaction rate constant of suplatast tosilate with hydroxyl radical
was calculated as 2.6×1011 M−1 S−1, which corresponded to the
diﬀusion limit.
4. Discussion
In the present study, we showed that, in a mouse model of hyperoxic
lung injury, treatment with suplatast tosilate ameliorated lung inﬂam-
mation, improved the survival rate, and prolonged survival.
Fig. 5. Numbers of total white cell (A) and neutrophils (B) in peripheral blood from mice
given water or suplatast tosilate during hyperoxic exposure. Blood was drawn from mice
given water (open bars) or suplatast tosilate (solid bars) at baseline and after 24, 48, 72,
and 90 h of hyperoxic exposure. Data are shown as the means± SEM (n=7 mice/group).
*p<0.05 versus mice given water.
Fig. 6. Oxidative stress assessed by measuring 8-OHdG in BAL ﬂuid (A), 8-isoprostane
(B), and MPO (C) in lung tissue. BAL was performed and lung tissues were obtained from
mice given water (open bars) or suplatast tosilate (solid bars) at baseline and after 24, 48,
and 90 h of hyperoxic exposure. Data are shown as the means± SEM (n=7 mice/group).
*p< 0.05, **p< 0.01.
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Administration of suplatast tosilate also signiﬁcantly decreased the
amounts of 8-OHdG in BAL ﬂuid and 8-isoprostane in lung tissue. In
addition, EPR spin-trapping analysis revealed that suplatast tosilate can
scavenge hydroxyl radicals. These results suggest that suplatast tosilate
protects against hyperoxic lung injury by decreasing the degree of
oxidative stress induced by ROS, particularly through its ability to
scavenge hydroxyl radicals.
The most interesting result of this study is that treatment of mice
exposed to hyperoxia with suplatast tosilate signiﬁcantly reduced the
amounts of both 8-OHdG in BAL ﬂuid and 8-isoprostane in lung tissue
compared with untreated mice exposed to hyperoxia. 8-OHdG is a
hydroxyl radical-damaged guanine nucleotide of nuclear and mitochon-
drial DNA that serves as a sensitive biomarker of in vivo oxidative DNA
damage [21]. Because alveolar epithelial cells represent a primary
target of hyperoxic lung injury [22], most 8-OHdG in BAL ﬂuid should
be derived from oxidatively damaged alveolar epithelial cells. The
ability of suplatast tosilate to reduce the 8-OHdG level in BAL ﬂuid
suggests that suplatast tosilate protected alveolar epithelial cells against
oxidative stress induced by hyperoxia. In turn, 8-isoprostane is a
speciﬁc product of lipid peroxidation formed in cell membranes by
ROS peroxidation of arachidonic acid that serves as a sensitive
biomarker of oxidative stress in tissue [23]. The ability of suplatast
tosilate to reduce the 8-isoprostane level in lung tissue suggests that
suplatast tosilate protected the lung against a broad range of oxidative
stresses induced by hyperoxia. These results indicate that orally
administered suplatast tosilate exerts a strong antioxidant activity in
vivo. Because the calculated dose of suplatast tosilate used in the
present study was higher than the dose for human use, further
experiments with a lower dose of suplatast tosilate should be con-
ducted.
Another notable ﬁnding of this study, obtained using EPR spin-
trapping analysis, is that suplatast tosilate was able to scavenge
hydroxyl radicals in vitro. The reaction rate constant of suplatast tosilate
with hydroxyl radicals was calculated as 2.6×1011 M−1 S−1, which is
faster than that of several well-established antioxidants, such as
Fig. 7. Assessment of Nrf-2 mRNA expression levels in mouse lungs after 72 h of
hyperoxic exposure. Expression level of Nrf-2 in lungs relative to the internal reference
18S rRNA was assessed in mice given water (open bar) or suplatast tosilate (solid bar)
after 72 h of hyperoxic exposure. Data are shown as the means± SEM (n=5 mice/
group). NS: not signiﬁcant.
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ascorbate, glutathione, and cysteine [24–26]. Because the hydroxyl
radical is the most reactive and harmful ROS and is considered
responsible for the development of hyperoxic lung injury [7,27,28],
we believe that this scavenging eﬀect of suplatast tosilate on hydroxyl
radicals was also exerted in vivo and thus protected the lung from
hyperoxic injury. In addition, we can suggest that another mechanism is
involved in the in vivo antioxidant activity of suplatast tosilate.
Suplatast tosilate absorbed by the digestive system is readily metabo-
lized into dimethyl sulﬁde (DMS) in various tissues [29–31]. Because a
previous study showed that DMS can exert a strong antioxidant activity
[32,33], DMS metabolized from suplatast tosilate in vivo might play an
unignorable role in protecting the lung against the oxidative stress
induced by hyperoxia. In addition, we are expecting that another
metabolite of suplatast tosilate, N-(4-(3-ethoxy-2-hydroxypropoxy)phe-
nyl)acrylamide, would also have strong antioxidant activities.
However, further study is necessary to elucidate this point.
In the present study, the protective role of suplatast tosilate against
hyperoxic lung injury was also shown by its ability to inhibit the
increases in the number of neutrophils and the levels of the pro-
inﬂammatory cytokines/chemokines IL-6 and MCP-1 in BAL ﬂuid from
hyperoxia-exposed mice. Hyperoxic lung injury is initiated by ROS-
induced damage of alveolar epithelial cells [7,8,34,35] and is followed
by the prominent inﬁltration of inﬂammatory cells into lung tissue
[36]. These inﬂammatory cells, particularly neutrophils and macro-
phages, generate ROS and cause a vicious cycle of oxidatively induced
lung injury. Therefore, the inhibitory eﬀect of suplatast tosilate on both
the numbers of neutrophils and levels of IL-6 and MCP-1 in BAL ﬂuid
suggests that suplatast tosilate breaks this vicious cycle in hyperoxic
lung injury.
In conclusion, suplatast tosilate protected the lung against oxidative
stress induced by hyperoxic exposure and prolonged the survival of
mice exposed to hyperoxia. This protective eﬀect appeared to be
mediated by the ability of suplatast tosilate to scavenge hydroxyl
radicals; however, we also speculate that DMS metabolized from
suplatast tosilate in vivo might be involved in this protection. Because
suplatast tosilate has been widely used as an asthma control drug in
Japan, the results of this study suggest that suplatast tosilate could also
be potentially used for the treatment of high oxidative stress-related
diseases of the lung such as hyperoxic lung injury and pulmonary
ﬁbrosis.
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